Supernus Pharmaceuticals(NASDAQ) SUPN

Supernus Pharmaceuticals helps people manage brain and nervous system conditions. It makes medicines for ADHD, epilepsy, and Parkinson's disease. These treatments aim to improve daily life for patients.

Helping the Brain and Body

• ADHD Treatments: Qelbree is a non-stimulant medicine for children and adults with attention-deficit hyperactivity disorder; net sales reached $89.2 million in the second quarter of 2026.
• Parkinson's Disease: GOCOVRI and ONAPGO treat movement issues like "off" episodes where symptoms return between doses; ONAPGO net product sales reached $13.5 million in the second quarter of 2026.
• Epilepsy and Migraine: Trokendi XR and Oxtellar XR manage seizures and prevent migraine headaches; net sales for both products fell 25% in the second quarter of 2026 due to competition from generic versions.
• Postpartum Depression: ZURZUVAE is an oral treatment for adults with depression following childbirth; the company shares all operating profits and losses equally with its partner, Biogen.
• Movement Disorders: MYOBLOC is an injectable toxin used to treat cervical dystonia, a condition causing neck muscle contractions, and excessive drooling in adults.

Strategic Deals and New Launches

• Entered a merger agreement with Indivior Pharmaceuticals on Aug. 1, 2026, to combine the two businesses into a larger neuroscience company.
• Acquired Sage Therapeutics in July 2025 to add the postpartum depression drug ZURZUVAE to its commercial portfolio.
• Launched ONAPGO in April 2025 as a new subcutaneous infusion device for patients with advanced Parkinson's disease.
• Secured the intellectual property and development rights for SPN-820 from Navitor on April 1, 2026, to expand its depression treatment pipeline.
• Expanded the label for Qelbree in January 2025 to include new data for breastfeeding mothers and pharmacodynamics.

Neuroscience Focus Without Factories

The company's focus on central nervous system disorders involves internal research and strategic acquisitions. It relies on third-party manufacturers for supply and packaging instead of operating its own production facilities.

Key Financial Performance Metrics

• Total revenue reached $219.1 million in the second quarter of 2026, up 32% year over year.
• Net loss was $60.7 million for the six-month period ended June 30, 2026, compared to net earnings of $10.7 million in the same period of 2025.
• Market cap grew to $2.7 billion in the second quarter of 2026, representing a 52.9% increase year over year.
• Collaboration revenue from ZURZUVAE reached $35.4 million in the second quarter of 2026.
• Cash, cash equivalents, and marketable securities totaled $372.1 million as of June 30, 2026.

Evolution Toward a New Future

Supernus has shifted from older epilepsy drugs toward new launches in ADHD and Parkinson's disease. Its planned merger with Indivior Pharmaceuticals represents a major transition into a larger specialized neuroscience entity.